

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of the groups n = 5

EQA round: E23/22 - Hormones 2

Deadline: 26.07.2022

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Test					Comparability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(393) C-peptide					24							18	18	100%
Samples and groups	[pmol/L]													
Sample A		384	83	22	24							18	18	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		381	32	8,3	8	0	CVPG	376	18	20%	300	452	8	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		448	26	5,9	8	0	CVPG	457	21	20%	365	549	8	
Other					8	0							2	
								2x 4/12, 1x 4/29, 2x 4/162, 1x 4/164, 2x 4/179						
Sample B		159	35	22	24							18	18	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		142	14	10	8	0	CVPG	140	8,0	20%	112	168	8	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		184	11	5,9	8	0	CVPG	189	11	20%	151	227	8	
Other					8	1							2	
								2x 4/12, 1x 4/29, 2x 4/162, 1x 4/164, 2x 4/179						
(193) Ferritin					34							32	31	97%
Samples and groups	[µg/L]													
Sample A		353	64	18	34							32	32	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		408	24	6,0	9	0	CVPG	395	9,0	24%	300	490	9	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		384	33	8,6	10	0	CVPG	367	4,3	24%	278	456	10	
Other					15	0							13	
								2x 4/12, 2x 4/29, 1x 4/149, 2x 4/162, 1x 4/179, 2x 6/1, 3x 6/58, 2x 6/60						
Sample B		40,3	9,3	23	34							32	31	97%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		37,2	4,7	13	9	0	CVPG	36,2	1,3 ±16,8		19,4	53	9	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		48,0	6,0	12	10	0	CVPG	44,4	0,76 ±16,8		27,6	61,2	10	
Other					15	0							13	
								2x 4/12, 2x 4/29, 1x 4/149, 2x 4/162, 1x 4/179, 2x 6/1, 3x 6/58, 2x 6/60						
(321) FSH					26							26	24	92%
Samples and groups	[U/L]													
Sample A		27,8	2,0	7,3	26							26	25	96%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		27,6	0,72	2,6	8	0	CVPG	27	0,30	15%	22,9	31,1	8	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		27,2	1,6	5,7	6	0	CVPG	26,4	0,57	15%	22,4	30,4	6	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		26,7	2,0	7,4	7	0	CVPG	27	0,16	15%	22,9	31,1	7	
Other					5	0							5	
								2x 4/162, 3x 4/179						
Sample B		15,0	1,1	7,4	26							26	24	92%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		14,6	0,96	6,6	8	0	CVPG	14,4	0,16	15%	12,2	16,6	8	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		16,0	1,5	9,3	6	0	CVPG	16,5	0,44	15%	14	19	6	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		14,6	0,94	6,5	7	0	CVPG	14,9	0,080	15%	12,6	17,2	7	
Other					5	0							5	
								2x 4/162, 3x 4/179						
(328) hGH					6							5	5	100%
Samples and groups	[mU/L]													
Sample A		26,5	1,6	6,2	6							5	5	100%
Other					6	0							5	
								1x 1/36, 4x 4/29, 1x 4/60						
Sample B		3,13	0,43	14	6							5	5	100%
Other					6	0							5	
								1x 1/36, 4x 4/29, 1x 4/60						
(329) IGF-1					8							8	8	100%
Samples and groups	[µg/L]													
Sample A		286	87	30	8							8	8	100%
Other					8	0							8	
								2x 4/29, 3x 4/60, 3x 4/164						
Sample B		116	40	35	8							8	8	100%
Other					8	0							8	
								2x 4/29, 3x 4/60, 3x 4/164						
(392) IGF-BP3					3							3	3	100%
Samples and groups	[µg/L]													
Sample A		3710	320	8,7	3							3	3	100%
Other					3	0							3	
								2x 4/29, 1x 4/60						

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of the groups n = 5

EQA round: E23/22 - Hormones 2

Deadline: 26.07.2022

Test	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability						N _{eva}	N _{suc}	S _{rel}
							AV	U _{AV}	D _{max}	LL	UL				
Sample B		3680	380	10	3								3	3	100%
Other					3	0							3		
2x 4/29, 1x 4/60															
(325) Insulin	[mU/L]				4								4	4	100%
Samples and groups															
Sample A		22,6	5,6	25	4								4	4	100%
Other					4	0							4		
2x 4/1, 1x 4/60, 1x 4/179															
Sample B		16,6	2,7	17	4								4	4	100%
Other					4	0							4		
2x 4/1, 1x 4/60, 1x 4/179															
(326) Folate	[nmol/L]				31								31	31	100%
Samples and groups															
Sample A		43,7	5,8	13	31								31	31	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		43,8	4,9	11	10	0	CVPG	46	1,1	27%	33,5	58,5	10		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		51,9	0,32	0,61	5	0	CVPG	49,9	1,0	27%	36,4	63,4	5		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		40,7	1,6	4,0	9	0	CVPG	40,5	0,48	27%	29,5	51,5	9		
Other					7	0							7		
2x 4/29, 1x 4/149, 2x 4/162, 2x 4/179															
Sample B		58,3	19	33	31								0		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		68,0	27	40	10	0	CVPG	62,8	6,1	27%	45,8	79,8	0		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		54,4	1,3	2,5	5	0	CVPG	53,6	1,1	27%	39,1	68,1	0		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		45,4	0,067	0,15	9	0	CVPG	45,4	0,054	27%	33,1	57,7	0		
Other					7	2							0		
2x 4/29, 1x 4/149, 2x 4/162, 2x 4/179															
(320) LH	[U/L]				25								25	24	96%
Samples and groups															
Sample A		75,3	11	15	25								25	24	96%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		68,4	2,8	4,1	8	0	CVPG	68,9	0,89	15%	58,5	79,3	8		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		66,6	2,8	4,2	6	0	CVPG	64,5	1,1	15%	54,8	74,2	6		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		86,5	3,7	4,2	6	0	CVPG	86,2	0,56	15%	73,2	99,2	6		
Other					5	0							5		
2x 4/162, 3x 4/179															
Sample B		7,49	1,8	24	25								25	25	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		5,77	0,19	3,3	8	0	CVPG	5,86	0,064	15%	4,98	6,74	8		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		7,68	0,33	4,3	6	0	CVPG	7,39	0,13	15%	6,28	8,5	6		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		9,89	0,47	4,7	6	0	CVPG	9,76	0,063	15%	8,29	11,3	6		
Other					5	0							5		
2x 4/162, 3x 4/179															
(407) Parathyroid hormone (PTH 1-84)	[pmol/L]				8								8	8	100%
Samples and groups															
Sample A		13,5	1,9	14	8								8	8	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		14,6	0,37	2,5	6	0	CVPG	14,8	0,57	17%	12,2	17,4	6		
Other					2	0							2		
2x 4/164															
Sample B		0,542	0,062	11	8								8	8	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		0,582	0,002	0,38	6	0	CVPG	0,581	0,0012 ± 0,204	0,377	0,785	6			
Other					2	0							2		
2x 4/164															
(405) Parathyroid hormone (PTH)	[pmol/L]				16								16	15	94%
Samples and groups															
Sample A		22,9	3,2	14	16								16	16	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		25,6	1,3	5,1	6	0	CVPG	25,4	0,41	23%	19,5	31,3	6		
Other					10	0							10		
3x 4/12, 1x 4/29, 2x 4/60, 2x 4/162, 2x 4/179															
Sample B		0,390	0,14	37	16								16	15	94%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		0,290	0,045	15	6	0	CVPG	0,352	0,025 ± 0,276	0,076	0,628	6			
Other					10	0							10		
3x 4/12, 1x 4/29, 2x 4/60, 2x 4/162, 2x 4/179															
(322) Prolactin	[mU/L]				27								27	27	100%
Samples and groups															
Sample A		571	76	13	27								27	27	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		612	48	7,9	10	0	CVPG	606	8,7	16%	509	703	10		

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of the groups n = 5

EQA round: E23/22 - Hormones 2

Deadline: 26.07.2022

Test	[unit]						Comparability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(322) Prolactin	[mU/L]				27							27	27	100%
--- Samples and groups ---														
Sample A		571	76	13	27							27	27	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		523	51	9,7	6	0	CVPG	514	8,8	16%	431	597	6	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		625	31	4,9	6	0	CVPG	619	4,0	16%	519	719	6	
Other					5	0							5	
								2x 4/162, 3x 4/179						
Sample B		197	30	15	27							27	27	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		213	16	7,6	10	0	CVPG	213	3,2	16%	178	248	10	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		177	8,2	4,6	6	0	CVPG	177	4,1	16%	148	206	6	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		224	18	8,2	6	0	CVPG	226	1,5	16%	189	263	6	
Other					5	0							5	
								2x 4/162, 3x 4/179						
(390) Renin	[ng/L]				6							5	5	100%
--- Samples and groups ---														
Sample A		46,3	3,0	6,6	6							5	5	100%
Other					6	0							5	
								1x 1/36, 4x 4/164, 1x 4/183						
Sample B		61,3	7,5	12	6							5	5	100%
Other					6	0							5	
								1x 1/36, 4x 4/164, 1x 4/183						
(394) SHBG	[nmol/L]				15							15	15	100%
--- Samples and groups ---														
Sample A		34,1	1,9	5,6	15							15	15	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		34,9	0,52	1,5	5	0	CVPG	32,3	0,26	20%	25,8	38,8	5	
Other					10	0							10	
								4x 4/1, 4x 4/12, 2x 4/29						
Sample B		61,7	5,0	8,0	15							15	15	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		65,0	1,4	2,2	5	0	CVPG	61,3	0,50	20%	49	73,6	5	
Other					10	0							10	
								4x 4/1, 4x 4/12, 2x 4/29						
(327) Vitamin B12	[pmol/L]				28							28	28	100%
--- Samples and groups ---														
Sample A		261	36	14	28							28	28	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		263	21	8,1	10	0	CVPG	256	5,6	20%	204	308	10	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		193	11	5,8	5	0	CVPG	186	4,9	20%	148	224	5	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		290	10	3,6	7	0	CVPG	287	2,5	20%	229	345	7	
Other					6	0							6	
								2x 4/29, 1x 4/149, 2x 4/162, 1x 4/179						
Sample B		903	120	14	28							28	28	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		960	110	12	10	0	CVPG	930	18	20%	744	1120	10	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		756	89	12	5	0	CVPG	754	19	20%	603	905	5	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		916	40	4,4	7	0	CVPG	919	5,2	20%	735	1110	7	
Other					6	0							6	
								2x 4/29, 1x 4/149, 2x 4/162, 1x 4/179						
(319) Vitamin B12 (active)	[pmol/L]				7							6	6	100%
--- Samples and groups ---														
Sample A		76,1	11	14	7							6	6	100%
Other					7	0							6	
								3x 4/1, 3x 4/60, 1x 4/179						
Sample B		274	27	10	7							0	0	
Other					7	0							0	
								3x 4/1, 3x 4/60, 1x 4/179						

st_kn_p

End of report

Printed: 30.07.2022